Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025

Rhea-AI Summary

Vericel (NASDAQ:VCEL) will present a fireside chat at the Stephens Annual Investment Conference on Thursday, November 20, 2025 at 11:00 a.m. ET (10:00 a.m. CT).

A live webcast will be available via the company’s Investor Relations website at http://investors.vcel.com, allowing investors and analysts to view the presentation in real time.

News Market Reaction – VCEL

+0.05%

1 alert

+0.05% News Effect

On the day this news was published, VCEL gained 0.05%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at 11:00 a.m. ET (10:00 a.m. CT) on Thursday, November 20, 2025.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2025 Vericel Corporation. All rights reserved.

Investor Contact: 
Eric Burns
ir@vcel.com
+1 (734) 418-4411

FAQ

When will Vericel (VCEL) present at the Stephens Annual Investment Conference?

Vericel will present on Thursday, November 20, 2025 at 11:00 a.m. ET (10:00 a.m. CT).

How can investors watch the Vericel (VCEL) presentation on November 20, 2025?

Investors can watch the live webcast at the company’s Investor Relations site: http://investors.vcel.com.

Will the Vericel (VCEL) fireside chat at Stephens 2025 be available after the event?

A webcast will be provided; check the Vericel Investor Relations site for any archived replay after the presentation.

What time is the Vericel (VCEL) fireside chat in Central Time?

The fireside chat is scheduled for 10:00 a.m. CT on November 20, 2025.

Where can I find more information about Vericel’s investor events and webcasts?

Visit Vericel’s Investor Relations website at http://investors.vcel.com for event details and webcast access.